Business
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
PASADENA, Calif., January 07, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease characterized by triglyceride levels that can be 10 to 100 times higher than normal leading to a substantially higher risk of developing acute, recurrent, and potent
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1609,"height":335,"url":"https://media.zenfs.com/en/business-wire.com/4f164f745268ecd10958a5fccee4519c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ziVmM8TclobUvlzY.NNi8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4f164f745268ecd10958a5fccee4519c","width":960,"height":200},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/oUFxRAHUmpqlFXe31SSwrQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/4f164f745268ecd10958a5fccee4519c","width":1200,"height":250}},"lazy":false},{"type":"text","content":"- REDEMPLO is being launched in China by Sanofi","length":47,"tagName":"p","attribs":{}},{"type":"text","content":"- NMPA approval triggers $10 million milestone payment to be paid by Sanofi to Arrowhead subsidiary Visirna Therapeutics","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"PASADENA, Calif., January 07, 2026--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease characterized by triglyceride levels that can be 10 to 100 times higher than normal leading to a substantially higher risk of developing acute, recurrent, and potentially fatal pancreatitis.","length":542,"tagName":"p"},{"type":"text","content":"REDEMPLO will be marketed in Greater China by Sanofi under an agreement between Sanofi and Arrowhead. In 2025, Sanofi purchased those rights from Visirna, a majority-owned subsidiary of Arrowhead created to develop and commercialize four of Arrowhead’s investigational cardiometabolic candidates in Greater China.","length":313,"tagName":"p"},{"type":"text","content":"Approval in China marks the third regulatory approval for REDEMPLO, following recent approvals by U.S. Food and Drug Administration (FDA) and Health Canada, as an adjunct to diet to reduce triglycerides in adults with FCS. REDEMPLO is also in review for marketing authorization by additional global regulatory authorities.","length":322,"tagName":"p"},{"t...